This transaction
Acquisition of Ishin Pharma as a SubsidiaryDevelopment, manufacture and sale of regenerative medicine products
The impact on the Company's consolidated results for the current fiscal year and subsequent periods is expected to be minor at this time. Over the medium to long term, the transaction is expected to contribute to an increase in the corporate value of the Company's Group.
| Item | Details |
|---|---|
| Transaction name | Acquisition of Ishin Pharma as a Subsidiary |
| Name of the Subject Company | イシンファーマ株式会社 |
| Business Description of the Subject Company | Development, manufacture and sale of regenerative medicine products |
| Location of the Subject Company | Chuo-ku, Tokyo |
| Capital Stock of the Subject Company | ¥100 million |
| Date of Establishment of the Subject Company | 3 September 2008 |
| Impact on Business Performance | The impact on the Company's consolidated results for the current fiscal year and subsequent periods is expected to be minor at this time. Over the medium to long term, the transaction is expected to contribute to an increase in the corporate value of the Company's Group. |
| Contract Date | Sequentially from 14 June |
| Execution Date / Effective Date | 6 July (scheduled) |
Items this document does not state (23)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The aim is to strengthen sales capabilities and enhance corporate value by leveraging Ishin Pharma's product development capabilities and the management resources of the Toho Holdings Group, while ensuring a more stable supply of regenerative medicine products to patients.